Kardigan, Inc.

Exhibit 99.1 PRESS RELEASE Kardigan Reports Third Quarter 2026 Financial Results and Recent Business Updates Completed enrollment in Cohort 2 of Phase 2b danicamtiv KINSHIP-DCM trial, topline data expected in 2Q 2027; Phase 3 enrollment underway in both cohorts Completed enrollment in Phase 2b ataciguat KATALYST-AV trial; Week 48 topline data expected in 2H 2027 Cash position of $591.4 million supports multiple data readouts across all programs through 2027 and initiation of Phase 3 clinic…

8-K · 2026-11-12 · 0001193125-26-456885

PRESS RELEASE Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence Supporting Patient Selection and Endpoints for the Evaluation of Ataciguat in Aortic Stenosis Primary endpoint of aortic valve calcium in KATALYST-AV to be assessed at Week 48 alongside aortic valve area and measures of cardiac structure and function; topline data expected 2H 2027 Novel real-world data help identify key markers of risk, rate of progression of disease and worsening outcomes in…

8-K · 2026-11-06 · 0001193125-26-451836

Exhibit 99.1 PRESS RELEASE Kardigan Announces Appointment of Kristin Reinke to its Board of Directors SOUTH SAN FRANCISCO, Calif., and PRINCETON, N.J., September 30, 2026 - Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan”), a precision cardiovascular company, announced today the appointment of Kristin Reinke to its Board of Directors, where she will serve as chair of the Audit Committee. As part of the Board’s public company evolution, Doug Giordano will be stepping down from the Board. Both Ms. R…

8-K · 2026-09-30 · 0001193125-26-408348

EX-99.1 2 ck0002123613-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 PRESS RELEASE Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates Continued to advance the development of three late-stage programs, supported by the Prolaio platform, aimed at addressing cardiovascular diseases where no approved treatments exist Danicamtiv KINSHIP-DCM Phase 3 Cohort 1 enrollment now underway; Phase 2b topline data expected 1H 2027 Strong cash position of $661 million followin…

8-K · 2026-08-11 · 0001193125-26-343395

Exhibit 4.4 KARDIGAN, INC. 2026 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Kardigan, Inc. 2026 Employee Stock Purchase Plan (the “Plan”) is to provide eligible employees of Kardigan, Inc. (the “Company”) and each Designated Company (as defined in Section 11) with opportunities to purchase shares of the Company’s voting common stock, par value $0.00001 per share (the “Common Stock”). 1,180,000 shares of Common Stock in the aggregate have been approved and reserved for this purpose, plus o…

S-8 · 2026-06-17 · 0001193125-26-274403

Exhibit 4.1 SPECIMEN SPECIMEN NUMBER SHARES SEE REVERSE Kardigan, inc. FOR CERTAIN DEFINITIONS INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE C o M M o n s T o C K This CerTifies ThaT: SPECIMEN - NOT NEGOTIABLE is The owner of FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF $0.00001 PAR VALUE EACH OF Kardigan, inc. transferable on the books of the Corporation in person or by attorney upon surrender of this certificate duly endorsed or assigned. This certificate and the shares repr…

S-1/A · 2026-06-11 · 0001193125-26-266629